Revance therapeutics, inc. (RVNC)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Revenue

58

89

46

0

278

488

2,362

686

193

37

75

75

75

75

75

75

75

75

75

75

75

75

75

75

158

309

158

75

75

Gross profit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

75

Operating expenses:
Research and development

39,794

27,493

25,847

25,526

23,995

25,542

21,848

22,871

22,239

21,002

21,643

18,307

19,409

12,529

10,296

15,192

12,364

14,956

13,016

10,303

9,254

9,129

8,600

8,110

7,551

6,238

6,284

7,782

7,527

Selling, general and administrative

21,224

18,766

16,739

13,596

12,910

13,358

14,155

12,734

13,616

11,887

9,148

8,609

7,754

7,100

7,502

7,018

7,455

6,905

5,827

6,360

5,996

4,793

5,300

4,857

4,093

3,003

2,142

3,641

2,225

Loss on impairment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1,949

-

-

0

0

-

-

-

-

-

-

-

-

-

Total operating expenses

61,018

46,259

42,586

39,122

36,905

38,900

36,003

35,605

35,855

35,816

30,791

26,916

27,163

26,739

17,798

24,159

19,819

21,861

18,843

16,663

15,250

13,922

13,900

12,967

11,644

9,241

8,426

11,423

9,752

Loss from operations

-60,960

-46,170

-42,540

-39,122

-36,627

-38,412

-33,641

-34,919

-35,662

-35,779

-30,716

-26,841

-27,088

-26,664

-17,723

-24,084

-19,744

-21,786

-18,768

-16,588

-15,175

-13,847

-13,825

-12,892

-11,486

-8,932

-8,268

-11,348

-9,677

Interest income

1,491

1,037

1,329

1,596

1,570

924

996

1,081

1,022

411

341

347

311

230

306

324

310

87

68

49

27

27

14

1

2

-

-

2

-

Interest expense

2,148

0

0

0

0

0

0

0

44

19

104

141

193

225

256

286

315

356

390

279

165

336

228

267

9,841

1,699

351

490

12,624

Change in fair value of derivative liabilities associated with convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

4,032

-

-

-

-

Changes in fair value of derivative liability

-90

-60

-68

21

-92

9

-45

-70

-34

-380

-44

-107

-60

-14

-167

-413

-14

67

13

89

-42

105

67

-76

-416

-

-

-

-

Change in fair value of common stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

2,151

-

-

-

-

Change in fair value of convertible preferred stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-210

-

-

-

-

Loss on settlement of preferred stock warrant

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-1,356

-

-

-

-

Other expense, net

-126

-133

-130

115

-155

-138

-144

-172

-319

-139

-128

-132

-126

-129

-138

-143

-125

-106

-98

-76

-47

-161

-5

-68

0

-364

-38

-4

2

Loss before income taxes

-61,833

-

-

-

-35,304

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-21,657

Income tax provision

100

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net Income (Loss) Attributable to Parent

-61,900

-45,296

-41,400

-37,400

-35,304

-40,617

-32,834

-34,080

-35,037

-35,906

-30,651

-26,874

-27,156

-26,832

-17,978

-24,602

-19,888

-22,094

-19,175

-16,805

-15,402

-14,212

-13,977

-13,302

-21,426

-10,079

-8,883

-11,829

-21,657

Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax

521

-39

-74

46

78

126

90

52

-276

42

72

-17

-52

-61

-132

-38

226

-50

22

-12

0

-

0

0

-

-

-

-

-

Comprehensive loss

-61,412

-45,365

-41,483

-37,344

-35,226

-40,491

-32,744

-34,028

-35,313

-35,864

-30,579

-26,891

-27,208

-26,863

-18,110

-24,640

-19,662

-22,144

-19,153

-16,817

-15,402

-

-13,977

-13,302

-

-

-

-

-

Net loss attributable to common stockholders:
Basic and diluted net loss

-61,933

-45,326

-41,409

-37,390

-35,304

-40,617

-32,834

-34,080

-35,037

-35,906

-30,651

-26,874

-27,156

-26,802

-17,978

-24,602

-19,888

-

-

-

-

-

-

-

-

-

-

-

-

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-19,175

-16,805

-15,402

-

-13,977

-13,302

-21,426

23,585

-12,793

-15,750

5,216

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-19,175

-16,805

-15,402

-

-13,977

-13,302

-21,426

16,277

-12,793

-15,750

13,349

Net loss per share attributable to common stockholders (Note 12):
Basic and diluted net loss (in dollar per share)

-1.15

-1.00

-0.96

-0.86

-0.85

-1.12

-0.91

-0.94

-0.97

-1.16

-1.01

-0.90

-0.94

-0.95

-0.64

-0.88

-0.71

-

-

-

-

-

-

-

-

-

-

-

-

Basic (in usd per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.81

-0.71

-0.65

-

-0.60

-0.69

-1.93

106.80

-55.92

-75.25

25.54

Diluted (in usd per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.81

-0.71

-0.65

-

-0.60

-0.69

-1.93

111.22

-55.92

-75.25

21.00

Weighted-average number of shares used in computing net loss per share attributable to common stockholders:
Basic and diluted weighted-average number of shares used in computing net loss per share (in shares)

53,868

45,669

43,314

43,260

41,598

36,339

36,272

36,123

35,950

31,549

30,270

29,776

28,808

28,203

28,160

28,089

28,005

-

-

-

-

-

-

-

-

-

-

-

-

Basic (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

23,755

23,584

23,535

-

23,331

19,380

11,092

238

228

209

204

Diluted (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

23,755

23,584

23,535

-

23,331

19,380

11,092

3,042

228

209

635